Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Liaoning Nuovino Pharmaceutical is a China-based pharmaceutical enterprise dedicated to the research, development, and industrialization of innovative small molecule therapeutics and high-end generic drugs. Headquartered in the Benxi High-tech Industrial Development Zone, the company focuses on high-prevalence therapeutic areas including metabolic diseases, oncology, and cardiovascular disorders. Its lead clinical candidate, NVN-01, is a potent URAT1 inhibitor currently being evaluated for the treatment of hyperuricemia and gout. Nuovino maintains comprehensive in-house capabilities ranging from medicinal chemistry and process development to GMP-certified manufacturing of APIs and finished dosages. The company aims to provide affordable, high-quality medical solutions for patients globally while leveraging its strategic location in China's Medicine Capital.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Liaoning Nuovino Pharmaceutical.